Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The ESMO Clinical Practice Guidelines on Metastatic non-small cell lung cancer (NSCLC) are based on results from recent studies and analyses. The guidelines focus on treatment recommendations for the management of advanced/metastatic NSCLC, with an update on the role of immunotherapy and the use of targeted therapies for patients with tumours with specific gene mutations. Also covered are personalised medicine recommendations and new treatment algorithms.

Updated 18 September 2019

To cite this article, please include the original citation Ann Oncol (2018) 29 (suppl 4): iv192–iv237 and this online publication: https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer

Table of Contents

The ESMO Clinical Practice Guidelines on Metastatic non-small cell lung cancer (NSCLC) are based on results from recent studies and analyses. The guidelines focus on treatment recommendations for the management of advanced/metastatic NSCLC, with an update on the role of immunotherapy and the use of targeted therapies for patients with tumours with specific gene mutations. Also covered are personalised medicine recommendations and new treatment algorithms.

Published 18 September 2019 by the ESMO Guidelines Committee

Download the current version from esmo.org (PDF)

Published in 2018 – Ann Oncol (2018) 29 (suppl 4): iv192–iv237

Download the original version from Annals of Oncology (PDF)